Valeant Pharmaceuticals

View All

Personalized Medicine
Valeant’s $50M; Sanofi vows; Top pharmas team up; PhRMA expels

Shadowed by nearly $30B in debt, Valeant's $50M guidance raise looks pretty paltry Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, one small positive development as it works to rebound from its noted downfall. The Canadian drugmaker reported first-quarter reven...

Find More